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STRUCTURED ABSTRACT  
Background: Sexual dysfunction is very common in patients with epilepsy. Objective: We 
sought to review the published literature around sexual dysfunction in epilepsy, and particularly the 
role played by anti-convulsant drugs. Method: We searched all related articles on PubMed using the 
search terms sexual dysfunction, various AEDs and epilepsy, and restricted the search to English 
language articles. Results: The most common manifestations of sexual dysfunction in patients with 
epilepsy are hyposexuality and erectile dysfunction. The cause of this dysfunction is multifactorial and 
overlapping, and includes changes in the levels of sex hormones, anti-convulsants, the epilepsy itself 
and psychosocial factors. Traditional anti-convulsants which induce the cytochrome P450 enzyme 
system have the highest rates of sexual dysfunction, which is primarily mediated by changes in sex 
hormone levels. Sexual dysfunction associated with newer anti-convulsants is likely to occur through 
different mechanisms. Some anti-convulsants such as oxcarbazepine and lamotrigine may improve 
sexual function, but can also rarely be associated with sexual dysfunction. Conclusion: 
Management of sexual dysfunction thought to be caused by anti-convulsants should include the 
cessation of the offending drug, and consideration of switching to alternative anti-convulsants that have 
been reported to improve sexual function such as oxcarbazepine, and lamotrigine. 
 
 
 
 
 
  
GRAPHICAL ABSTRACT  
 
 
 
Both epilepsy and AEDs causes sexual dysfunction mediated by changes in sex hormones. They can 
also cause mood disturbances, which can lead to sexual dysfunction. AEDs can also cause sexual 
dysfunction directly, by affecting neural transmission in pathways that are important for the sexual 
response. 
 
 
 
 
  
 1. INTRODUCTION 
 Epilepsy is one of the most common, serious, chronic neurological conditions in the world and 
it is becoming increasingly evident that a number of factors affect quality of life and well being in men 
and women with epilepsy beyond simple seizure control (1). However, historically, gender differences 
in epilepsy focused mainly on women with epilepsy, and issues around menstrual cycles, contraception 
and pregnancy. More recently there has been increasing awareness of the differing impact of epilepsy 
and antiepileptic drug (AED) treatment on sexual function in both men and women (1) and that sexual 
well-being is critical for a good quality of life in patients with epilepsy (2).  
 
When discussing sexual dysfunction in epilepsy, the first step is to define both normal and 
abnormal sexual function (sexual dysfunction). Given the central, mechanistic role played by sex 
hormones in sexual dysfunction, it is also important to be aware of the basic metabolism and regulation 
of sex hormones. Furthermore, the aetiological basis of sexual dysfunction in patients with epilepsy is 
likely to be multifactorial and a number of different variables need to be considered such as the 
epilepsy itself, the AEDs used to treat it, and psychosocial factors. This is a narrative review on sexual 
dysfunction is epilepsy with special attention to the role of anti-epileptic drugs (AEDs). We searched 
all related articles on PubMed using the search terms sexual dysfunction, various AEDs and epilepsy, 
and restricted the search to English language articles.  
 
2. SEXUAL DYSFUNCTION: DEFINITIONS AND CLASSIFICATION 
 Sexual dysfunction can be defined as a chronic inability to respond sexually in a way that is 
satisfying (3). Any discussion of sexual dysfunction demands oversight of the normal physiology of 
sexual function, and an understanding of the classification of sexual dysfunction.  
The sequence of events that characterizes the progression from the sexually unaroused to the 
aroused state, and the resolution of these changes, has been described as the human sexual response 
cycle. It can be divided into several phases: desire, excitement, orgasm, and resolution (4). Sexual 
desire can be defined as a willingness to engage in sexual behaviour and can come about spontaneously 
(proceptive desire) or by activation through sexual excitation (responsive desire) in response to 
appropriate sexual stimuli (4). Androgens are thought to be essential to support sexual desire in both 
men and women (5–8). Sexual excitement and its physiological counterpart, sexual or genital arousal, 
are defined as the capacity to respond to appropriate sexual stimuli which can be psychogenic (arising 
in the brain and triggered by input from the special senses or by conscious sexual fantasies) or 
reflexogenic arising from stimulation of genital and/or erotogenic sites (breasts, nipples, inner thighs, 
perineum) (4). It is mediated by androgens and estrogens, in men and women respectively (5–8), 
although testosterone is also important in women and there is laboratory evidence that it increases 
vaginal blood flow (9). Genital arousal consists of penile erection in men and clitoral tumescence, 
genital vasocongestion, and increased vaginal lubrication in women. The increase in heart rate, and 
blood pressure that occur during sexual arousal ensure there is increased blood flow to the genitals. 
These changes facilitate the sexual response in men, whose purpose is to allow the introduction of 
sperm into the vagina. The changes in women enable painless penile penetration and thrusting, and 
encourage sperm survival and transport (4). 
A robust classification of sexual dysfunction in patients with epilepsy is critical not only for 
the diagnosis and management, but also for research, in these patients. However, many published 
studies in patients with epilepsy do not use any well-recognised classification systems. Given the 
multifactorial and often unknown basis of sexual dysfunction, a descriptive, rather than aetiologically 
based, organisation has been commonly used in defining sexual dysfunction.  A significant problem 
associated with such a classification system is the assumption of mind versus body dualism whereby 
the disorder is either psychiatric or medical in aetiology (10). The most commonly used classification 
systems are the International Classification of Diseases, 10
th
 Edition (ICD-10) (3) and the Diagnostic 
and Statistical Manual of Mental Disorders (fifth edition; DSM-V) (11) (Table 1). Although the DSM 
is a psychiatric system, some of its diagnostic criteria have been used to define conditions that are 
assumed to have an organic aetiology. This is a historical precedent. Before the advent of 
phosphodiesterase inhibitors, psychiatrists or psychologists initiated most treatment of sexual disorders, 
and it was widely presumed that most sexual disorders had psychological origins (12). The most recent 
version of the DSM (DSM-V) (11) separates out sexual dysfunction according to sex for the first time, 
and is no longer based on the sexual response cycle as proposed by Masters and Johnson (4). 
 
 
Major Classification Systems of Sexual Dysfunction (adapted from McCabe et al(12)) – Table 1 
ICD-10 Definitions of Sexual Dysfunction Not Caused by an Organic Disorder or Disease* 
Lack or loss of sexual desire Loss of sexual desire is the principal problem and not secondary to other sexual problems such as erectile failure or dyspareunia. Lack of sexual desire does 
not preclude sexual enjoyment or arousal but makes initiation of sexual activity less likely. 
Sexual aversion Strong negative feelings associated with the prospect of sexual interaction resulting in avoidance of sexual activity. 
Lack of sexual enjoyment Sexual responses and orgasm occur normally but there is lack of appropriate pleasure. 
Failure of sexual response In men the principal problem is difficulty in getting and/or maintaining an erection (erectile dysfunction). Provided there is no organic aetiology to erectile 
dysfunction (eg diabetes or hypertension) erections may occur normally in certain situations such as masturbation, or sleeping with a different partner. 
In women the primary problem is vaginal dryness or failure of lubrication.  
Orgasmic dysfunction Orgasm does not occur or is markedly delayed. 
Premature ejaculation The inability to control ejaculation sufficiently for both partners to enjoy sexual interaction. In severe cases, ejaculation might occur before vaginal entry or 
in the absence of an erection. 
Non-organic vaginismus Spasm of the muscles that surround the vagina, causing occlusion of the vaginal opening and resulting in painful or impossible penile entry. Can often be 
due to local cause of pain in which case that should be coded. 
Dyspareunia Pain in women (or men) during sexual intercourse. Can often be due to local pathology in which case that condition should be coded. Category should only 
be used when there is no other primary sexual dysfunction (eg. vaginal dryness).  
Excessive sexual drive When excessive sexual drive is secondary to another disorder such as dementia or an affective disorder then the underlying disorder should be coded. 
DSM-5 Definitions of Sexual Dysfunction** 
Female sexual interest-arousal disorder Lack of, or significantly reduced sexual interest or arousal is manifested by at least three of the following characteristics: 
- absent or decreased interest in sexual activity 
- absent or decreased sexual or erotic thoughts or fantasies 
- no or decreased initiation of sexual activity 
- absent or decreased sexual excitement or pleasure during sexual activity in at least 75% of sexual encounters 
- absent or decreased sexual interest or arousal in response to any internal or external sexual or erotic cues 
- absent or decreased genital or non-genital sensations during sexual activity in at least 75% of sexual encounters 
Female orgasmic disorder Marked delay/infrequent/absent orgasms during at least 75% of sexual activity OR decreased intensity of orgasmic sensations during at least 75% of sexual 
activity 
Female genito-pelvic pain-penetration disorder Persistent or recurrent difficulties with at least one of the following 
- vaginal penetration during intercourse 
- vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts 
- marked fear or anxiety about vulvovaginal or pelvic pain in anticipation, during or as a result of vaginal penetration 
- marked tensing or tightening of pelvic floor muscles during attempted vaginal penetration 
Male hypoactive sexual desire disorder Persistent or recurrent deficient (or absent) sexual or erotic thoughts or fantasies and desire for sexual activity. 
Male erectile disorder Experience during at least 75% of sexual activity of at least one of the following 
- difficulty in obtaining an erection 
- difficulty in maintaining an erection until completion of sexual activity 
- marked decrease in erectile rigidity 
Male premature (early) ejaculation Persistent or recurrent pattern of ejaculation within approximately 1 minute of vaginal penetration and before an individual wishes it. 
Male delayed ejaculation Either marked delay in ejaculation OR infrequent/absent ejaculation during at least 75% of sexual activity 
*ICD-10 organic sexual dysfunction codes include erectile dysfunction, vaginismus, and dyspareunia of organic aetiology. 
**DSM-V specifies that problems should have persisted for at least 6 months and have occured on approximately 75% or more of sexual occasions, and cause clinically significant distress, in order to be classified as 
sexual dysfunction. Symptoms should not be the consequence of a non-sexual mental disorder, severe relationship distress or attributable to the effect of a medication or illness. 
 2.1. Sex Hormone Synthesis and Metabolism (figure 1 adapted from (13)) 
The release of the sex steroid hormones is controlled by the hypothalamic-pituitary-gonadal 
axis. The major sex steroid hormones are testosterone from the testis and estrogen and progesterone 
from the ovaries. The adrenal gland also makes a significant contribution to androgen production. 
Peripheral conversion to other biologically active steroid forms occurs in the skin and adipose tissue.  
 
The control centre of the reproductive system is the nuclei of the medial basal hypothalamus. 
Sex hormone synthesis is controlled by the pulsatile release of hypothalamic gonadotropin-releasing 
hormone (GnRH). At the pituitary gland GnRH stimulates the release of leuteinizing hormone (LH) 
and follicle simulating hormone (FSH) into the general circulation. LH binds to its target cells, which 
are the Leydig cells in the testes of the males, and theca cells in ovaries of females.  
 
In men testosterone and other androgens such as dehydroepiandrosterone (DHEA), 
dehydroepiandrosterone sulphate (DHEAS) and androstenedione are produced in the zona 
reticulate/fasciculata of the adrenal cortex, and the Leydig cells, which are adjacent to the seminiferous 
tubules of the testes. Testosterone itself exists in three different forms in the bloodstream, namely free 
(2-3%), albumin bound (53-55%) and sex hormone binding globulin (SHBG) bound (43-45%). While 
free testosterone and part of the albumin bound testosterone are available to tissues, the SHBG portion 
is unavailable to tissues and is not considered biologically active. Testosterone is converted to 
dihydrotestosterone (DHT) by the action of 5α-reductase in target tissues. Although this steroid is 
much less abundant than testosterone, it accounts for most of testosterone’s biological action. 
Androgens are also synthesised in females either from circulating precursors in their target tissues, or 
in the zona reticularis of the adrenal glands, and the ovarian stroma. DHT is also produced in females, 
but in low quantities and is mainly produced in peripheral target tissues. Testosterone, but not DHT, is 
converted to estradiol (E2) by the action of aromatase in certain peripheral tissues, and is an important 
source of estrogens in some women.  
 
In women estrogens are produced in the granulosa and theca cells of the ovaries as well as the 
corpus luteum. The theca cells are stimulated by LH to produce pregnenolone, which is eventually 
converted to androstenedione. The androstenedione is converted to estrone (E1) by aromatase in the 
granulosa cells of the ovary, which is then converted to estradiol (E2) by 17β-HSD. The expression of 
aromatase and 17β-HSD is controlled by FSH stimulation. Aromatase is also expressed in non-gonadal 
tissue and facilitates the peripheral conversion of androgens to estrone (E1). Estrogens are also made in 
males in peripheral tissues that express aromatase (eg. Leydig cells and Sertoli cells in testes), which 
convert circulating testosterone to estradiol (E2) and androstenedione to estrone (E1). These estrogens 
act and are metabolised locally, which limits their systemic effects.  
 
 Progesterone is synthesized from pregnenolone by action of 3β-HSD in the corpus luteum, by the 
placenta during pregnancy, and by the adrenals, as a step in androgen and mineralocorticoid synthesis. 
Its actions are primarily mediated by an intracellular progesterone receptor, whose numbers increase in 
the presence of estrogen. 
 
2.2. Sex Hormone Regulation (13) (figure 2) 
The sex hormones are regulated by the hypothalamic-pituitary-gonadal axis. Regions of the 
hypothalamus that are involved in the regulation, production, and secretion of gonadotrophin-releasing 
hormone (GnRH) receive direct connections from the cerebral hemispheres including the 
temporolimbic structures such as the amygdala (14,15). Functionally distinct regions of the amygdala 
exert opposing modulatory effects on pituitary hormone secretion (16). As a result of these intimate 
connections, epileptiform discharges from the temporal lobe may be transmitted through the amygdala-
hippocampal pathways, and disrupt the normal pulsatile secretion of gonadotrophic hormones, and 
basal levels of dopamine secretion, resulting in hypogonadism and hyperprolactinaemia(17).  
 
In men, the pulsatile release of GnRH from the hypothalamus causes the secretion of the 
gonadotropins LH and FSH into the circulation. While LH stimulates the release of testosterone from 
Leydig cells, the testosterone feeds back negatively on pituitary LH and hypothalamic GnRH. 
Estradiols generated by the peripheral aromatisation of testosterone may also give rise to negative 
feedback, although they can also contribute to sexual behaviour in a positive fashion in men (18).  FSH 
stimulates the release of inhibin from Sertoli cells, which feeds back to inhibit the anterior pituitary 
release of FSH, and also stimulates spermatogeneis. Hormonal regulation in women is more 
complicated than in men because the feedback effects of different hormones vary depending on the 
stage of the menstrual cycle. As in men GnRH release by the hypothalamus results in the release of LH 
and FSH at the anterior pituitary. Feedback from theca cells of the ovarian follicle occurs via the 
release of progestins, while feedback from the granulosa cells of the ovarian follicle occurs via the 
release of inhibin and estradiol. Progesterone and estradiol are also released by the corpus luteum 
which develops from the ovarian follicle in the post-ovulatory phase of the menstrual cycle.  
 
2.3. Neuroanatomy of Sexual Function 
Over the last 20 years, non-invasive functional imaging with positron emission 
tomography (PET) and magnetic resonance (fMRI) has highlighted those regions of the brain 
that are thought to be important for sexual function. They include, amongst others, the limbic 
and paralimbic regions, which are thought to be important for sexual motivation, and parietal 
areas that modulate emotional and motor responses (19). The autonomic nervous system 
connects the central nervous system to the genitalia and mediates genital engorgement, erections, 
ejaculation, and climax. Several components of the autonomic system are particularly important. 
The superior hypogastric plexus is a network of fibres anterior to the lower abdominal aorta and 
is connected with the pelvic (inferior hypogastric) plexus by the hypogastric nerves. The pelvic 
plexus itself has connections with sacral roots S2 to S4 through the pelvic splanchnic nerves, 
while the lumbosacral motorneurons also receive central projections from the ventral tegmental 
region of the brainstem which is thought to be important in sexual function (19). 
 
 
  
The metabolism of sex hormones - Figure 1 
Pink – Early processing steps are common to multiple areas including the adrenal cortex, Leydig cells 
of the testes and theca cells of the ovaries. 
Grey – These steps convert androgens from the theca cells into estogens in the granulosa cells of the 
ovary and peripheral tissues; the reactions are carries out by aromatase. Aromatase and 17β-HSD are 
found in peripheral tissues. 
Yellow – These steps convert testosterone into more potent DHT and occur in peripheral tissues such 
as the skin, prostate and epididymis of the testis. 
* Note DHEA is converted to DHEA-S in the adrenal cortex , which stimulates androgen secretion. 
 
 The hypothalamic-pituitary-gondal axis in males and females - Figure 2 
Shaded boxes represent anatomical structures while unshaded boxes represent hormones. Unbroken 
lines indicate positive feedback, Dotted lines indicate negative feedback. Red colouring indicates 
structures or hormones found predominantly in females. Blue colouring indicates indicates structures 
or hormones found predominantly in males. Black/gray colouring indicates structures or hormones 
found in both sexes. 
 3. SEXUAL DYSFUNCTION IN MEN AND WOMEN WITH EPILEPSY: THE SIZE OF THE 
PROBLEM 
 Sexual dysfunction affects between 30 to 66% of men (20) with epilepsy and 14 to 50% of 
women (20). The variability in these figures is related to a number of limitations common to 
epidemiological studies and which include, lack of a control groups, selection bias, differing adopted 
clinical instruments and cultural backgrounds. Different groups or types of patients with epilepsy are 
assessed in different studies, and not always compared with control groups. Varying methods of 
assessment of sexual dysfunction are also used in patients, each with their own problems. Those studies 
that have used clinical interviews are often non-blinded, and unclear in their definitions of sexual 
dysfunction. Face-to-face interviews may result in a selection bias toward more sexually experienced 
subjects, and have higher drop out rates. There is some evidence to suggest that men are more likely to 
over-report and women to under-report sexual experiences (21). Conversely, the use of questionnaires 
is not without problems. Although there is a broad array of questionnaires that have been used in 
normative populations and subsequently applied to epilepsy patients, none have been formally 
validated in patients with epilepsy. Regardless of methodology, all types of studies are typically limited 
by confounding factors such as concurrent physical or psychiatric disease, and the location of the 
patient populations studied. These tend to be tertiary centres where patients either have refractory 
epilepsy, or are pre-surgical candidates. Theoretically therefore, the findings of these studies may not 
be representative of the epilepsy population at large. Finally, the cultural background of patients can 
influence results. For example, a cross-sectional study carried out in Egypt (22) reported no increase in 
sexual dysfunctions but all types of sexual dysfunction in women with epilepsy in Egypt were less 
common than in normal control women in the United States, suggesting that cultural factors may play a 
major role in the willingness to admit to, or even recognise, symptoms of sexual dysfunction. 
 
3.1. Women with Epilepsy 
 At least 20 to 30% of women with epilepsy may suffer from sexual dysfunction (23). The 
nature of this sexual dysfunction consists primarily of reduced sexual desire, or orgasmic dysfunction. 
One of the earliest studies by Bergen et al. (24) evaluated 50 women with epilepsy in a tertiary epilepsy 
care centre, 32 of whom had focal epilepsy, and 28 of whom were taking only one AED. Patients and a 
matched control group were asked how often they had the desire for sex, and how often they had 
sexual intercourse. Though equal proportions of women in both groups had a frequent desire for sex, 
more controls had a very frequent desire compared with none in the epilepsy group. In addition, a 
larger proportion of patients compared to controls had very infrequent sexual desire, and 20% of 
patients reported that they almost never had sexual desire. This difference could not be explained by 
access to a sexual partner, and there was no correlation with age, prescribed antiepileptic drugs, 
duration of epilepsy, or seizure type. The authors concluded that there was a significant proportion of 
patients with epilepsy who have markedly decreased sexual desire compared to the general population.  
 
In contradiction to this finding other studies report that the main type of sexual dysfunction in 
patients with epilepsy is not a reduction in sexual desire, but orgasmic dysfunction or other physical 
symptoms. Morrell et al. (21) conducted a study of 116 women with epilepsy attending a tertiary 
centre, using patient self-report questionnaires, which included the Sexual Arousability Inventory 
Expanded (SAI-E), Sexual Behaviour Inventory (SBI), and Sexual Functioning Inventory (SFI). 
Compared with historical controls this group of women did not have less sexual desire, but did report 
less overall sexual satisfaction. Specifically, 18% (9%), 28% (7%), 39% (8%) and 42% (14%) of 
women with focal epilepsy had global anorgasmia, vaginismus, dyspareunia and arousal insufficiency 
respectively (figures in brackets represent controls). In women with generalised epilepsy, 31% (9%), 
13% (7%), 19% (8%) and 33% (14%) had global anorgasmia, vaginismus, dyspareunia and arousal 
insufficiency respectively (figures in brackets represent controls). Although the women with epilepsy 
in this study did not have less sexual experience than controls, they reported more sexual anxiety, 
which may have contributed to problems with sexual arousal.  Indeed, Duncan et al. (25) in a tertiary 
clinic based study of 195 women with epilepsy who completed the Frenken Sexuality Experience scale 
also reported higher levels of inadequate orgasmic satisfaction compared to healthy controls. They also 
reported that women with epilepsy desired intercourse as much as healthy controls, but were more 
‘moral’ and less open to sexual experiences. Jensen et al. (26) studied sexuality in 48 women with 
epilepsy, and compared their findings to patients with diabetes mellitus and healthy controls. Although 
the authors found no difference in sexual desire between the three groups, 19% of the women with 
epilepsy had orgasmic dysfunction compared with 11% of the diabetes mellitus group and 8% of the 
controls. They found no correlation between sexual dysfunction and type and duration of epilepsy, or 
AED use. A recent, large study (27) highlights both reduced sexual desire and orgasmic dysfunction 
and other physical symptoms in women with epilepsy. They used a study specific questionnaire to 
assess 171 in- and out-patients with epilepsy in a tertiary centre. The most common forms of sexual 
dysfunction in descending order were reduced sexual desire, problems with orgasm, vaginal dryness 
and pain during intercourse. They also reported that 75% of women compared with 12% of controls 
had sexual dysfunction, which was associated with a poorer quality of life and depression.  
 
Despite the clear importance of psycho-sexual factors in sexual dysfunction as noted above, there is 
also direct support for physiological impairment of sexual function in women with epilepsy, including 
orgasmic dysfunction. Morrell et al. (28) measured genital blood flow in nine women with temporal 
lobe epilepsy as they watched erotic or neutral videos. Blood flow was significantly reduced in the 
women with epilepsy compared to healthy controls as they watched erotic material. There was no 
difference in mood between the two groups, but the women with epilepsy were less sexually 
experienced and more anxious when imagining specific sexual activities compared to controls. 
 
3.2. Men with Epilepsy 
 Anywhere between 20 and 70% of male patients with epilepsy are affected by sexual 
dysfunction, which can include loss of sexual desire, reduced sexual activity or sexual arousal, 
anorgasmia and erectile dysfunction (29–31). Although the prevalence figures differ between studies 
(32), erectile dysfunction consistently appears to be more common in patients with epilepsy than 
healthy controls, and indeed other neurological disorders (33). In the study (27) described above, 
63% of men suffered from sexual dysfunction compared with 10% of controls. This manifested as 
erectile dysfunction, reduced sexual desire, premature ejaculation and problems with orgasms in order 
of decreasing incidence. This finding is corroborated by other studies which have reported 
hyposexuality and erectile dysfunction in up to 80% of patients with refractory epilepsy (34,35). 
Reassuringly studies in different patient populations report similar findings. One community study (36) 
reported that 57% of men with epilepsy and attending their general practioner had erectile dysfunction 
compared with 18% of controls, and 39% had ejaculatory failure compared with 0% of controls. 
 
Although erectile dysfunction appears to be common in men with epilepsy, it is also a 
common problem in the general population and elderly men. It is associated with a number of variables 
including age, smoking, physical activity and educational level in individuals without co-existing 
medical conditions, in addition to common medical conditions such as diabetes and hypertension (37). 
This might explain why some studies report conflicting results in men with epilepsy suggesting no 
differences in sexual dysfunction between patients with epilepsy and healthy controls (26,32). In an 
attempt to resolve this problem a population-based case control approach has been taken by some 
groups (38). This study looked at 6,427 patients with erectile dysfunction and 32,135 controls matched 
for age. After adjusting for hypertension, diabetes, hyperlipidemia, renal disease, coronary heart 
disease, obesity, alcohol abuse/alcohol dependence syndrome, and socioeconomic status, conditional 
logistic regression analysis revealed that patients with erectile dysfunction were more likely to have 
been diagnosed with prior epilepsy than controls (OR = 1.83, 95% CI = 1.51-2.21). Compared with 
controls, the adjusted ORs for prior generalized epilepsy and focal epilepsy for cases were 2.13 (95% 
CI = 1.52-3.00) and 1.64 (95% CI = 1.31-2.06), respectively. The most pronounced associations were 
detected in erectile dysfunction cases aged between 30 and 39 who were 3.04 (95% CI = 1.67-5.50) 
times more likely than controls to have been previously diagnosed with epilepsy. Moreover, the authors 
of this study point out that these figures may be an underestimation, because erectile dysfunction 
remains a taboo subject in Taiwan where the study was based. 
 
As was the case for women, despite the clear importance of psycho-sexual factors in sexual 
dysfunction, there is also direct evidence for physiological factors causing the impairment of sexual 
function in men with epilepsy, including erectile dysfunction. In addition to the nine women studied by 
Morrell et al. (28) discussed above, reduced genital blood flow compared to controls was reported in 
eight men with temporal lobe epilepsy as they watched erotic or neutral videos. 
  
4. AETIOLOGY OF SEXUAL DYSFUNCTION IN EPILEPSY (Figure 3) 
 There is a significant body of evidence that demonstrates that sex hormone levels are altered 
in patients with epilepsy, and that patients have higher levels of endocrine reproductive disorders. In 
exploring the link between these observations and sexual dysfunction in epilepsy, two issues arise. 
Firstly, it is unclear how much of the alteration in sex hormones is due to AEDs (39), and how much is 
due to the ictal/interictal discharges associated with the epilepsy, or any underlying structural 
abnormality, both of which are well recognised as causing reproductive endocrine disorders (16,31). 
On the one hand, there are studies that have demonstrated sexual dysfunction and reproductive 
endocrine abnormalities in drug naive patients highlighting the fact that epileptiform discharges or 
underlying structural abnormalities may be causative factors (17,40,41). Indeed, epileptic discharges 
can be associated with abnormal testosterone and gonadotrophin levels, altered LH response to GnRH 
stimulation and increased serum prolactin concentrations (42). In contrast, other studies have shown no 
difference in sex hormone levels between patients having seizures and those off AEDs with no seizures 
(43), suggesting that ictal and interictal discharges in epilepsy may only partly explain sex hormone 
abnormalities. Other studies highlight the role of AEDs in hormone levels in patients with epilepsy. For 
example one study prospectively measured hormone levels after enzyme inducing AED withdrawal in 
seizure free patients, and demonstrated increases in biologically active testosterone levels 4 months 
after drug withdrawal compared to baseline (44).  
  
The second issue that arises is that despite the number of studies that independently demonstrate high 
levels of sexual dysfunction and reproductive endocrine disorders in patients with epilepsy, there is not 
a consistent correlation between the two observations (45,46). Indeed, it is clear that reproductive 
endocrine disorders do not always lead to sexual dysfunction in people without epilepsy (5–8). In 
patients with epilepsy, although some studies show a clear concordance between sex hormone levels 
and sexuality in patients with epilepsy (45,47,48), other studies have failed to show such a concordance 
(26,46,49).  The reason for this discrepancy is likely to be the multi-factorial basis of sexual 
dysfunction in epilepsy, which includes not only changes in sex hormone levels caused by the epilepsy 
(ictal/interictal discharges +/- structural basis) itself and AEDs, but also psychosocial factors, and 
disturbances in neurotransmission, not all of which are mediated by changes in sex hormones (figure 
3). Some of these other factors are related to AED use and will therefore be discussed in this review.  
 
4.1. Effect of Antiepileptic Drugs on Hormone Levels 
 Evidence for a correlation between sexual dysfunction and hormonal changes in patients with 
epilepsy comes primarily from the multiple studies that have shown that changes in SHBG are 
associated with sexual dysfunction (50). A consistent finding is that patients treated with older AEDs 
(carbamazepine, phenytoin and barbiturates) which are potent inducers of the cytochrome P450 
enzyme system typically have lower levels of free and bioactive testosterone than those treated with 
non-inducing AEDs such as lamotrigine or levetiracetam (39,46,51–53). While total testosterone levels 
do not differ among patient groups, SHBG is significantly elevated among patients on enzyme 
inducing AEDs. This, in turn, leads to lower levels of unbound, biologically active testosterone and 
higher serum gonadotrophin levels, which may contribute sexual dysfunction seen in this patient group
 
(52,54–57). Enzyme inducing drugs may also induce aromatase, which converts testosterone to 
estradiol (E2), which inhibits LH secretion and may contribute to a drop in testosterone levels and 
sexual dysfunction (30). In a landmark study, Herzog et al. (45) studied a group of 85 men with a focal 
epilepsy syndrome (25 on carbamazepine, 25 on phenytoin, 25 on lamotrigine and 10 on no AEDs). 
Controls included men without epilepsy. Sexual function scores were obtained by a self-reported 
questionnaire (S-score questionnaire), and serum measurements included bioactive testosterone (BAT), 
bioactive estradiol (BAE), BAT:BAE ratio, sex hormone binding globulin (SHBG), and LH. Gonadal 
efficiency was defined as the ratio BAT:LH. Nearly 25% of men with epilepsy had sexual dysfunction, 
and S-scores were lower in men taking enzyme-inducing AEDs (EIAEDs), which in this study were 
men taking carbamazepine or phenytoin, compared to men with epilepsy taking lamotrigine or 
compared to controls. BAT levels correlated with S-scores for men with epilepsy taking EIAEDs. 
BAT, BAT:BAE and BAT:LH ratios were lower in men taking EIAEDs compared to controls or 
patients taking lamotrigine.  
 
Similar findings are apparent in women with epilepsy. Morrell and et al. (58) studied 57 
reproductive-aged women with either localization related (LRE) or primary generalized epilepsy (PGE) 
on antiepileptic drug (AED) monotherapy and 17 non-epileptic controls. They completed several 
questionnaires assessing sexual experience (sexual behaviour inventory), arousability (sexual 
arousability inventory), anxiety (sexual anxiety interview), and symptoms of depression. An endocrine 
assessment was performed during the early follicular phase of the menstrual cycle. Compared to non-
epileptic controls, women with epilepsy had significantly higher sexual dysfunction scores, lower mean 
arousal, and higher depressions scores. Mean arousal scores were also lower in the PGE group. Women 
on EIAEDs (in this study defined as carbamazepine, phenobarbital and phenytoin) when combined into 
one group had significantly higher sexual dysfunction and lower sexual arousal compared to controls. 
This was not the case in women taking enzyme-inhibiting AEDs (sodium valproate) or enzyme neutral 
AEDs (gabapentin, lamotrigine) Furthermore, estradiol levels negatively correlated with sexual 
anxiety, and dehydroepiandrosterone sulfate (DHEAS) was negatively correlated with sexual 
dysfunction and positively correlated with sexual arousal. 
 
Other studies involving AEDs that do not induce cytochrome P-450 enzymes appear to support the 
concept that these AEDs have little effect on sex hormones (45,46). In a randomised prospective study 
of patients taking non-enzyme inducing AEDs and randomised to either valproate or lamotrigine 
monotherapy no changes in total testosterone or free testosterone were noted after 6 to 12 months of 
treatment in either treatment group (59). 
 
4.2 Psychiatric Disorders 
 Despite the aforementioned studies, other reports have failed to demonstrate a correlation 
between hormonal changes in patients with epilepsy and sexual function (31). Part of the reason for 
this may be psychiatric comorbidities, which may also contribute to sexual dysfunction in patients with 
epilepsy (58,60).  Talbot et al. (46) evaluated sexual function, anxiety and depression with the Hospital 
Anxiety and Depression scale in 60 men with epilepsy receiving AED monotherapy and 60 controls. 
They reported that while patients taking EIAEDs did have lower levels of free testosterone compared 
to patients taking newer anti-convulsants, most patients had levels of testosterone that should be 
adequate for sexual functioning. Moreover, they found no correlation between testosterone levels and 
sexual function, and no difference in sexual function between men taking enzyme inducing and non-
enzyme inducing medications. Instead they found that sexual function correlated with levels of anxiety 
and depression, suggesting that reductions in sexual desire and self-belief in being able to behave 
sexually were related to a patient’s mood. Although this study classified oxcarbazepine and topiramate 
as enzyme inducing drugs, which may have confounded results, other reports have also shown that 
anxiety and depression can have an impact on sexual desire and erectile function in patients with 
epilepsy (49). Conversely, other studies have shown that hypogonadism in epilepsy can manifest as an 
affective disorder with loss of energy and competitive drive (16,61), and that testosterone treatment in 
epilepsy patients with hypogonadism can lead to significant improvements in mood (61). More 
recently, a systematic review has confirmed for the first time a bidirectional association between 
depression and sexual dysfunction (62). Given that it is well documented that a number of AEDs 
including barbiturates, vigabatrin, and topiramate can cause adverse mood effects (63), this therefore is 
a potential mechanism by which AEDs can cause sexual dysfunction. 
 
4.3. Epileptic Factors 
Aside from AEDs and psychiatric factors, structural and physiological factors associated with 
the epilepsy itself may also contribute to sexual dysfunction in patients with epilepsy. Patients with 
focal seizures, and especially temporal lobe epilepsy (TLE) appear to be more prone to hypogonadism 
and sexual dysfunction than patients with generalised epilepsy syndromes (14,15,24,54,64,65). This 
finding is corroborated by both animal (66), and clinical studies that have shown that a significant 
proportion of patients develop an improvement in sexual function after temporal, but not extra-
temporal lobe, surgery for their epilepsy (67), and that a normalisation of serum androgens can occur 
after surgery even in patients with maintained AEDs (68). This is perhaps not surprising given the links 
between mesial temporal lobe structures like the amygdala and the hypothalamus-pituitary-gonadal 
axis. Fixed lesions or epileptiform discharges affecting these areas may therefore predispose to sexual 
dysfunction. Moreover, some studies suggest that there is a lateralisation effect such that patients with 
right sided lesions and right TLE are more likely to have sexual dysfunction, and this may relate to 
lateralisation in the central regulation of gonadotrophin secretion and its disruption by ictal and 
interictal discharges (69,70). These findings suggest that beyond seizures and AEDs, structural and 
physiological factors associated with the epilepsy, may also have a role to play in the development of 
hormonal abnormalities that may mediate sexual dysfunction in patients with epilepsy.  
 
4.4. Neurotransmission changes 
 Calabro highlights another mechanism by which AEDs might cause sexual dysfunction in 
patients with epilepsy (30,71). He proposes that AEDs might inhibit and disrupt the normal 
neurotransmission of sexual excitement and arousal, which may lead to sexual dysfunction. These 
mechanisms which do not rely on changes in sexual hormone levels may be particularly relevant to 
newer, non-enzyme inducing AEDs. They include enhancement of GABAergic inhibition and 
unbalancing of the cerebral serotonin/dopamine ratio (carbamazepine, phenobarbital and phenytoin), 
AMPA receptor blockade through inhibition of the glutamatergic pathway (topiramate), the impairment 
of the complex interplay between serotonergic and nitrergic pathways (zonisamide), or the reduction of 
central nervous system excitatory transmission by unbalancing the dopamine/serotonin ratio 
(oxcarbazepine, levetiracetam) (71,72). 
 
4.5. Psychosocial factors 
 Psychosocial factors may also have a role to play in the aetiology of sexual dysfunction in 
patients with epilepsy. Stigmatization, psychological distress, low self-esteem and fear of rejection may 
lead to social isolation and feelings of inadequacy that contribute to sexual dysfunction. In a survey of 
quality of life of people with epilepsy in Europe, many subjects reported low levels of satisfaction with 
sexual relationships, partly because they felt stigmatized by having epilepsy (73). 
 
 
The multi-factorial nature of sexual dysfunction in epilepsy - Figure 3 
Both epilepsy (which includes ictal/interictal discharges +/- structural cause of epilepsy) and AEDs can 
give rise to sexual dysfunction which is mediated by changes in sex hormones. 
However both epilepsy and AEDs can also cause mood disturbances which can lead to sexual 
dysfunction which may also be mediated by changes in sex hormones. Conversely, sexual dysfunction 
and hypogonadism may lead to mood disturbance. AEDs can also cause sexual dysfunction directly by 
affecting neural transmission in pathways that are important for the sexual response. Finally, social 
factors caused by epilepsy can also lead to sexual dysfunction. 
5. SPECIFIC AEDS AND SEXUAL DYSFUNCTION IN EPILEPSY (Table 2) 
Having discussed the multiple mechanisms thorough which AEDs may affect sexual function, we will 
now describe the specific types of sexual dysfunction and how commonly they arise in patients with 
epilepsy. Given the multivariate nature of sexual dysfunction in epilepsy, sexual dysfunction can only 
reliably be ascribed to AEDs in several circumstances; where randomised clinical trials report sexual 
dysfunction as a side effect, where sexual dysfunction is reported in a comparative, cross-sectional 
study between patients on different AEDs, or between patients taking AEDs and healthy controls, and 
finally in case reports or series where sexual dysfunction arises after commencement of an AED and 
ceases when the AED is discontinued. 
 
5.1. Carbamazepine 
As the archetypical enzyme inducing AED, carbamazepine is probably the most common 
AED to cause sexual dysfunction in men and women. In the study by Herzog et al. (45) described 
earlier sexual function scores were below the control range in 32.0%, 24%, 20% and 4% of patients on 
carbamazepine phenytoin, no AEDs, and lamotrigine respectively. These findings are corroborated by 
other studies. In an observational, cross-sectional study of 90 men comparing the effects of valproate, 
carbamazepine and oxcarbazepine to healthy controls, 7 of the 18 men (18%) taking carbamazepine 
had diminished sexual dysfunction (52). These were the highest rates amongst the patients studied.  
 
The most commonly reported types of sexual dysfunction reported in patients taking 
carbamazepine are decreased libido, erectile dysfunction and orgasmic dysfunction. In two multi-
centre, randomised, controlled trials Matson et al. (74,75) reported that 7% of 231 and 13% of 101 
patients with epilepsy taking carbamazepine developed decreased libido or impotence respectively 
during a one year follow-up period. Reis et al. (76) conducted a controlled cross-sectional study in 63 
men receiving carbamazepine for temporal lobe epilepsy. Using the International Index of Erectile 
Function (IIEF-5) questionnaire they reported that 41/63 (65.1%) patients with epilepsy had erectile 
dysfunction compared with 4/55 (7.3%) control subjects, all of which were mild cases. Kuba et al. (77) 
evaluated the incidence of sexual dysfunction and hormonal profile in men with focal epilepsy. They 
prospectively analysed sexual function using the International Inventory of Erectile Function (IIEF), 
but without a control group. The authors noted that all patients with orgasmic dysfunction were being 
treated with carbamazepine (CBZ) in monotherapy or combination therapy. In patients with at least one 
type of sexual dysfunction, they also found a higher proportion of valproate treatment in monotherapy 
or combination therapy in comparison with CBZ. The other AEDs patients were taking in this study 
included lamotrigine, levetiracetam, topiramate and valproate. The other types of sexual dysfunction 
that have been reported in the use of carbamazepine are much rarer and limited to single case reports, 
including ejaculatory failure (78) and hypersexuality (79). 
 
5.2. Oxcarbazepine 
Oxcarbaxepine is a carbamazepine derivative, but is metabolised by different pathways and unlikely to 
induce liver enzymes unless used at higher doses (>900mg/day) (80,81). Most studies indicate that it 
has a low incidence of sexual dysfunction associated with its use, and in some cases can improve 
sexual function. Rattya et al. (52) observed that in 29 patients with epilepsy taking oxcarbazepine 
monotherapy for an average of 2.4 years, 5 patients had diminished sexual function, while 1 had 
enhanced sexual function. Despite the limitations of this study in its lack of use a validated sexual 
function questionnaire, the study also showed that while valproate increased serum androgen 
concentrations in men with epilepsy, the endocrine effects of carbamazepine and oxcarbazepine were 
different. Carbamazepine appeared to decrease the bioactivity of androgens, whereas oxcarbazepine 
did not have this effect, which is consistent with its relative lack of adverse effect on sexual functioning 
at conventional doses. The other reports of sexual dysfunction caused by oxcarbazepine are limited to 
case reports and include anorgasmia (82), anejaculation (83), and a combination of both symptoms 
(84). In all of these cases symptoms resolved on discontinuation of oxcarbazepine, and in two of the 
three cases effects were seen only at 1800mg daily of oxcarbazepine. 
 
Several studies have also suggested that oxcarbazepine can improve sexual function, especially if used 
in patients who have developed carbamazepine related sexual dysfunction. Luef et al. (85) conducted a 
prospective study in 228 male epileptic patients who had pre-existing sexual dysfunction and were 
treated with oxcarbazepine. After 12 weeks 181 (79.4%) of patients had improved sexual function, and 
23 (10.1%) had no sexual dysfunction. In those patients who had been pre-treated with carbamazepine 
the improvement was most marked. Smaller case series report identical findings, namely resolution of 
erectile dysfunction when patients are switched from carbamazepine to oxcarbazepine (86). 
 5.3. Phenytoin 
 Phenytoin, like carbamazepine, has a high preponderance to causing sexual dysfunction. In 
the blinded, randomised controlled trial reported by Mattson et al. (74) 11% of 110 patients with focal 
or secondarily generalised seizures taking phenytoin experienced impotence during a 12 month 
treatment period. These findings are replicated in smaller cross-sectional studies. Herzog et al. (45) in 
the study described above, reported that after carbamazepine, phenytoin was the most likely drug to be 
associated with sexual dysfunction developing in 24% of male patients taking the drug, compared to 
20% of patients with epilepsy and taking no AEDs. As an enzyme inducing drug phenytoin is 
associated with increased SHBG levels, and reduced serum levels of free testosterone. However, it is 
also associated with an increase in estradiol levels (64,87) suggesting that it may also induce 
aromatase, which converts free testosterone to estradiol. Although estradiol only makes up 1% of a 
male’s total steroid sex hormone, it exerts powerful negative feedback on male LH secretion, and 
increases the synthesis of SHBG, all of which contribute to a hypogonadotrophic hypogonadism state 
(88).  
Similar effects on sexual function are apparent in female patients with epilepsy. One study 
(58)  reported that sexual dysfunction and anxiety were significantly higher, and sexual arousal 
significantly lower, in 27% of female patients taking phenytoin compared to healthy controls. There are 
also case reports that phenytoin may rarely cause retrograde ejaculation in male patients with epilepsy 
(89). 
 
5.4. Phenobarbital 
 As an enzyme inducing AED, phenobarbital, and its structural analogue primidone, 
have been shown to increase SHBG levels and decrease free testosterone and estradiol levels (90). 
Correspondingly, cross-sectional studies have demonstrated prevalence rates of up to 22% 
patients suffering with decreased libido and impotence (74). 
 
5.5. Sodium Valproate 
Sodium valproate is a first generation AED that inhibits, rather induces, liver enzymes. In the 
randomised, controlled trail reported by Mattson et al. (75) 10% of the 240 patients taking sodium 
valproate developed impotence or reduced libido during a one-year follow-up period. Cross-sectional, 
observational studies report similar results. One study (91) reported that a group of 25 male patients 
treated with sodium valproate reported worse erectile function as measured by a simplified version of 
the International Index of Erectile Function Scale (IIEF-5), when compared to healthy controls. 
Interestingly however, these patients also reported satisfactory sexual intercourse. This unexpected 
observation may be consistent with the finding by Rattya et al. (52) that in 21 male patients taking 
sodium valproate only 1 (5%) reported diminished sexual function, while 4 patients (19%) reported 
enhanced sexual function. In this study sexual function was considered enhanced if the patient reported 
increased libido, potency, or increased satisfaction with erection or orgasms, and was diminished if the 
patient reported no interest in sex, or decreased libido, potency, or decreased satisfaction with erection 
and orgasm. It is therefore possible that some of the patients reporting enhanced sexual function may 
also have had erectile difficulties, in addition to increases in other sexual domains. Given that androgen 
levels were increased as a group in these patients, it is possible that some of these effects may have 
been mediated by these hormonal changes. In women it is well documented that women can develop 
hyperandrogenic states and polycystic ovarian syndrome with the use of sodium valproate (ref drugs 
and sex/reproductive dysfunction review) but the link between these reproductive endocrine 
abnormalities and sexual function is much less clear (8). 
5.6. Lamotrigine 
There is an increasing body of evidence to suggest that lamotrigine may improve sexual 
function. Whether this is a direct effect of lamotrigine, or an indirect effect mediated by the mood 
enhancing effects of lamotrigine is less clear. Gil-Nagel et al. (92) conducted a prospective, unblinded 
study in 141 patients treated with lamotrigine over 8 months using the Changes in Sexual Functioning 
Questionnaire (CSFQ). Of these patients, 79 patients initiated treatment with lamotrigine monotherapy, 
and 62 were switched to lamotrigine because of lack of efficacy or adverse events to a previous AED. 
In women who started treatment with lamotrigine, a significant improvement was observed, both in 
total CSFQ score, and in the five dimensions of the scale (desire/frequency, desire/interest, pleasure, 
arousal/excitement and orgasm). In men, a significant improvement was only observed in the pleasure 
dimension. In the group of patients in whom a previous AED was substituted by lamotrigine, 
significant improvement was recorded in the dimensions of pleasure and orgasm in men and 
desire/frequency in women. Although the results of this study could be ascribed to direct or indirect 
effects of lamotrigine, other factors that might be involved include improvement of the epilepsy, 
changes in quality of life, and elimination of side effects from other AEDs. However, the results of this 
study are also supported by two other important results. Herzog et al. (45) reported sexual dysfunction 
in 20% of untreated patients, but a lower rate of 4% of patients treated with LTG. In a cross-sectional 
study by Svalheim et al. (53) the sexual function of 40 women and 37 men receiving lamotrigine 
monotherapy for 6 months was evaluated using the Arizona Sexual Experience Scale Score (ASEX). 
The ASEX test is designed to assess five major aspects of sexual dysfunction: drive, arousal, vaginal 
lubrication/ penile erection, ability to reach orgasm, and satisfaction from orgasm. Sexual function 
across all categories was significantly better in female, but not male, patients taking lamotrigine 
compared to healthy controls and those patients taking carbamazepine. The findings of this study, 
despite its methodological differences, are in accordance with that by Gil-Nagel et al. (92) in 
suggesting that lamotrigine has an effect on improving sexual function, particularly in women. In 
addition to the large studies described, there are also a number of case reports, and case series 
describing improvements in sexual function when patients are switched from other AEDs to 
lamotrigine (93). 
 
5.7. Levetiracetam 
Levetiracetam is a relatively new, widely used, broad spectrum AED. Svalheim et al. (53) in 
the cross-sectional study described earlier also studied the effects of levetiracetam on sexual and 
hormonal function in 30 men and 26 women over 6 months using the ASEX rating scale.  The authors 
reported that there were no specific hormonal changes associated with levetiracetam in men or women, 
but like lamotrigine it was associated with improved sexual function across almost all categories of the 
ASEX compared with controls in women only. However there are also reports of levetiracetam being 
associated with a decrease in sexual function such as decreased libido (94), but it should be noted that 
these are small case series or individual case reports, and interestingly all in men. In the study (91) 
described earlier, although hormonal levels were no different in 20 male patients taking levetiracetam 
compared to controls, the patient group as whole scored worse on International Index of Erectile 
Function Scale (IIEF-5).   
 
5.8. Topiramate 
Topiramate is an AED that is approved for the treatment of both focal and generalised 
epilepsy syndromes, and for migraine prophylaxis. Overall it appears to be associated with a low 
incidence of sexual dysfunction. Holtkamp et al. (95) were one of the first to report 2 cases of erectile 
dysfunction from their case series of 40 patients who had been treated with topiramate for focal 
epilepsy. The dosage of topiramate reached ranged from 100mg/day to 200mg/day, and symptoms 
resolved on discontinuation of the medication. This low rate of sexual side effects, despite its 
widespread use across two indications, is reflected in the small number of case reports documenting 
similar side effects (96–98). 
 
5.9. Pregabalin 
Pregabalin is an AED that is structurally related to gabapentin, and is used for pain and 
anxiety, as well as epilepsy. The incidence of sexual dysfunction appears to be low and is typically 
related to erectile dysfunction or anorgasmia. Hitiris et al. (99) reviewed the incidence of sexual 
dysfunction related to pregabalin in placebo-controlled trials across several of its indicated uses. In the 
placebo-controlled trials of pregabalin in epilepsy, 363 males received PGB and 156 males received 
placebo. Impotence was reported by 11 (3.0%) men taking PGB and three (1.9%) on placebo, which 
amounted to an insignificant difference between groups. The dose of pregabalin reached ranged from 
150mg/day to 600mg/day. Across all placebo-controlled trials for all indications, a total of 2428 males 
received PGB, 71 (2.9%) of whom reported the adverse event of impotence. In these same trials, 1099 
males received placebo with eight patients (0.7%) reporting impotence. Sexual dysfunction was not 
reported by female patients with epilepsy receiving treatment with PGB during the epilepsy trials and 
only in 3 patients (0.1%) across the entire population treated with PGB. A small number of case reports 
appear to support this finding of rare complications of angorasmia and erectile dysfunction, which are 
reversible on cessation of pregabalin (100,101). 
 
5.1.0. Gabapentin 
Gabapentin is widely used in migraines, paraesthesia, neuralgia, bipolar disorder and epilepsy. 
Sexual dysfunction is an uncommon side effect of gabapentin, and published data is limited to case 
reports despite its multiple indications. The most common symptom is anorgasmia, which can be seen 
at doses from 900mg/day to 3600/day in all indications, and may be more common in elderly patients 
(102,103). Symptoms are reversible on cessation of the drug. 
 
5.1.1. Other AEDs 
Both zonisamide and lacosamide are relatively new AEDs. To date there is only one case 
report for each AED reporting sexual dysfunction (72,104). In both cases male patients reported 
erectile dysfunction, and a decrease in libido in the case of lacosamide. Symptoms resolved on 
cessation of the offending AED. To our knowledge no sexual dysfunction has been reported following 
use of brivaracetam, perampanel, felbamate and eslicarbazepine. 
 Drug Most commonly reported types 
of sexual dysfunction 
How common? Nature of evidence 
First generation AEDs 
Carbamazepine Decreased libido 
Erectile dysfunction 
Orgasmic dysfunction 
*** Randomised controlled trials 
Cross-sectional studies 
Phenytoin Decreased libido 
Erectile dysfunction 
*** Randomised controlled trials 
Cross-sectional studies 
Phenobarbital Decreased libido 
Erectile dysfunction 
*** Randomised controlled trials 
Cross-sectional studies 
Primidone Decreased libido 
Erectile dysfunction 
*** Randomised controlled trials 
Cross-sectional studies 
Sodium valproate Decreased libido 
Erectile dysfunction 
** Randomised controlled trials 
Cross-sectional studies 
Modern AEDs 
Oxcarbazepine Improved sexual function ** Cross-sectional studies 
Lamotrigine Improved sexual function ** Prospective study 
Cross-sectional studies 
Levetiracetam Improved sexual function 
 
Decreased libido (men only) 
* 
 
* 
Cross-sectional studies 
 
Case series/Case reports 
Topiramate Erectile dysfunction * Case reports 
Pregabalin Erectile dysfunction * Randomised controlled trials 
Case reports 
Gabapentin Orgasmic dysfunction * Case reports 
Zonisamide Erectile dysfunction 
 
* Case reports 
Lacosamide Erectile dysfunction 
Decreased libido 
* Case reports 
 
Summary of Anti-Convulsants and Effects on Sexual Function – Table 2 
* = rare, ** = common, *** = very common 
 6. MANAGEMENT OF SEXUAL DYSFUNCTION RELATED TO AEDS 
 The use of AEDs in patients with epilepsy is clearly associated with the frequent occurrence 
of sexual dysfunction in both men and women. However, the relationship between sexual dysfunction, 
hormones, seizures and AEDs remains unclear. In addition, the psychosocial complications associated 
with epilepsy may also affect sexual health. Given the multifactorial nature of this problem, it is 
perhaps not surprising that there is little research in this challenging area, and there are no guidelines or 
expert consensus statement on the management of sexual dysfunction induced by AEDs in patients 
with epilepsy. Regardless of this, some general principles of management cab be applied to this 
population. 
 
Firstly, when prescribing an AED to a patient with epilepsy there should be awareness that 
any pre-existing sexual dysfunction, depression or anxiety may facilitate the development and 
progression of sexual dysfunction. In any evaluation of a patient with epilepsy presenting with 
symptoms of sexual dysfunction, management of the patient should be guided by an awareness of the 
multifactorial nature of the problem. To this end, any history taking from the patient should also 
include a thorough medication history, sexual/relationship history and screening for anxiety and 
depression. Besides AEDs there are numerous other classes of drugs commonly prescribed in this 
patient population that can cause sexual side effects including anti-depressants, neuroleptics, sedatives, 
and beta-blockers. Questionnaires for assessing sexual dysfunction may prove a useful adjunct by 
allowing quantification of the problem, especially in patients who may be embarrassed to discuss their 
sexual problems. Two widely used scales are the Arizona Sexual Experience Scale (ASEX) and the 
International Index of Erectile Function score (IIEF). However, it should be noted that neither of these 
instruments nor others have been validated in an epilepsy population. Further assessment of the patient 
should include a general and urogenital as well as standard neurological examination, particularly as 
erectile dysfunction can be the first manifestation of cardiovascular disease. Blood tests should include 
a metabolic and endocrinological screen, including serum levels of testosterone, SHBG, DHEAS, 
estradiol, LH, FSH, prolactin, and thyroid function. 
 
In those patients in whom sexual dysfunction is thought to be due to the AED, switching to an 
alternative AED should be considered. As discussed above, the most commonly reported positive 
switch is from carbamazepine to oxcarbamazepine, although there is also some evidence to suggest that 
switching to lamotrigine may also be helpful. Phosphodiesterase type 5 inhibitors (PDE5) may also 
have a role in those patients with erectile dysfunction where a switch in AEDs is not possible or useful 
(29,86,105). However, caution is also needed because tonic-clonic seizures have been reported in 
patients taking PDE5 medications (106). 
 
Ultimately, improvements in the management of sexual dysfunction secondary to AEDs in patients 
with epilepsy, is contingent on a deepening of our understanding of this area. Further research into the 
incidence and specific nature of sexual dysfunction for individual AEDs, and the dosages at which they 
occur, would enable better counselling of patients when they commence AEDs. A better understanding 
of the mechanisms that cause AEDs, especially non-enzyme inducing AEDs, to give rise to sexual 
dysfunction would help to improve treatment of these patients. These should be the areas of focus of 
robust, high quality research in the future. 
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